Forgot your password?
New user?
Nanoparticle fear over anti-odour socks
Fragment-based Lead Discovery Conference 2008
test conference
Document Actions
Choosing the Right Target in Drug Discovery
| Type | Conference |
|---|---|
| Date |
May 15, 2013 from 09:30 am to 06:30 pm |
| Venue |
Society of Chemical Industry 14/15 Belgrave Square London, SW1X 8PS GB |
| Chemistry Specialties |
|
| Chemistry Techniques |
|
| Contact |
Jacqui Colgate Society of Chemical Industry 14/15 Belgrave Square London, SW1X 8PS GB +44 (0)20 7598 1561 +44 (0)20 7235 7743 jacqui.colgate@soci.org |
| Add event to calendar |
vCal (Windows, Linux)
iCal (Mac OS X)
|
This symposium will cover the current approaches to novel target selection in drug discovery. The differentiation of drug candidates through on- and off-target mechanisms and pathways will be discussed. Methods for target validation, mechanism clarification, measuring or predicting tractability, efficacy and safety will be covered to show how a better understanding of these interacting effects can allow the development of better quality Lead and Clinical Candidates.
An exhibition is being planned during the refreshment and lunch breaks. There will
be a limited number of spaces available for companies and related organisations who
may wish to exhibit. For further information and prices please send an email to conferences@soci.org with “Choosing the Right Target exhibition information“ as the title.
Speakers
09.30 Registration and refreshments
09.55 Welcome and introductions
10.50 Targeting multi-protein regulatory systems: Allostery and protein- protein interactions
Tom Blundell, University of Cambridge
10.50 Phenotypic vs target screening approaches – black or white or shades of grey
Graeme Walker, AstraZeneca
11.30 The genomics of drug sensitivity in cancer: preclinical biomarker discovery in cancer cells
Mathew Garnett, Sanger Institute
12.10 Lunch and exhibition
13.30 The expanding role of the medicinal chemist: application of chemical tools to enhance biological target selection
Ian Storer, Pfizer Neusentis
14.10 RNAi screening: pitfalls and bear-traps
Michael Howell, London Research Institute, CRUK
14.50 Mode of action analysis and biomarker discovery by phospho-proteomics
Christian Eckert, Evotec, Germany
15.30 Refreshment break
16.00 Drug Discovery Toxicology: approaches to improving candidate drug safety
Peter Newham, AstraZeneca
16.40 Selection and validation of cancer drug targets: Objective computational assessment and chemical tools
Paul Workman,The Institute of Cancer Research, London
17.30 Closing remarks and Wine reception (Evotec)
Other topics
Drug Discovery